Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
CCTG is launching the New-Investigator Cancer Trials Practicum to provide better engagement and training of new investigators with practical work in the field to allow for succession planning of top cancer trialists.
The Central Operations and Statistics Office is seeking nominations for the 2018 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group. We are seeking nominations for the following Recognition Awards: Founder's Award: Dr. Joseph Pater Excellence in Clinical Trials Research
The CCTG HN.9 study has been centrally activated in Canada, as of January 31.
HN.9 is a Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC), 2018.
The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Lung Disease Site Committee Executive and the Quality of Life Committee.
The preferred candidates will have a combination of academic and clinical experience, with demonstrated clinical expertise in family medicine, will exhibit strong potential for innovative and scholarly research, and provide evidence of an ability to work in an interdisciplinary, collaborative environment. Clinical responsibilities will be based at the Queen’s Family Health Team in Kingston and include taking call approximately one (1) night per month and three (3) weekends per year.